Design, Synthesis, Bioactivity, and Docking Studies of Isatin-Hydrazone Derivatives as Potential CDK-2 Inhibitors

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Chemical Biology

Background:

• Isatin derivatives are nitrogen-containing heterocycles with diverse pharmacological activities.
• Hydrazone compounds are crucial in pesticide and medicinal chemistry.
• Combining isatin and hydrazone skeletons may yield potent biological activity.

Purpose of the Study:

• Synthesize novel isatin-hydrazone derivatives.
• Evaluate their potential as Cyclin-Dependent Kinase 2 (CDK2) inhibitors.
• Investigate their anticancer properties through molecular docking and bioactivity studies.

Main Methods:

• Synthesis and characterization of isatin-hydrazone derivatives using NMR and HRMS.
• In vitro cytotoxicity assessment via MTT assay against A549, HepG2, and HeLa cancer cell lines.
• Molecular docking to analyze binding interactions with the CDK2 active site.

Main Results:

• Compounds 2e and 2f showed potent activity against A549 (IC50 = 5 nM) and HeLa (IC50 = 6 nM) cells, respectively.
• Compound 2h exhibited dual efficacy against A549 (IC50 = 8 nM) and HepG2 (IC50 = 13 nM) cells.
• Molecular docking confirmed strong binding affinities of active derivatives to the CDK2 active site.

Conclusions:

• Novel isatin-hydrazone derivatives, specifically 2e, 2f, and 2h, demonstrate significant potential as anticancer agents.
• These compounds effectively inhibit CDK2 kinase activity.
• The synthesized derivatives warrant further investigation as therapeutic candidates for cancer treatment.